Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN

De qué trata este estudio

El registro no identifica actualmente este estudio como reclutando. Consulta su estado antes de planificar una evaluación.

Tipo de estudio

De intervención

Fase

No aplica

Rango de edad

18 años - 70 años

Sexo admitido

Todos los sexos

Voluntarios sanos

No aceptados

Participantes

204 Estimado

Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.

Acerca de la investigación

Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks. Eligible subjects are randomly assigned to the experimental group and the control group at a ratio of 2:1. The experimental group is treated with the ultrasound nerve ablation catheter and the ultrasound nerve ablation device of Shenzhen Maiwei Medical Technology Co., Ltd., while the control group only undergoes renal arteriography (regarded as a sham operation). Within 6 months after the operation, both groups continue to receive antihypertensive drug treatment with the dosage and types specified during the screening period. The subjects are kept blinded during the study. The relative change values of the average 24 - hour ambulatory systolic blood pressure from the baseline at 6 months after the operation are compared between the two groups.

¿Quién podría participar?

La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.

Inclusion Criteria:

1. Age between 18 and 70 years old (calculated based on the date of starting standardized medication).
2. After treatment with at least two types of antihypertensive drugs for 4 weeks or more, the clinic systolic blood pressure is ≥140 mmHg and ≤180 mmHg, and the average 24 - hour ambulatory systolic blood pressure is ≥130 mmHg (or the daytime ambulatory systolic blood pressure is ≥135 mmHg).
3. Resting heart rate ≥70 beats per minute without taking beta - blockers (this criterion does not apply to patients taking beta - blockers).
4. The subject agrees to participate in this clinical trial, complies with the follow - up required by the trial protocol, and has voluntarily signed the informed consent form

Exclusion Criteria:

1. CTA, MRA, or DSA examination shows that the shape and structure of the unilateral or bilateral renal arteries are not suitable for ablation surgery (renal artery stenosis exceeding 50%, renal artery aneurysm, fibromuscular dysplasia of the renal artery, or the diameter of the main renal artery is less than 3 mm).
2. Having only one kidney or having received a kidney transplant.
3. Having a history of renal artery interventional treatment or renal denervation surgery.
4. Suffering from any condition that may affect the accuracy of blood pressure measurement, such as the upper arm diameter being too large relative to the cuff.
5. Secondary hypertension (excluding apnea syndrome).
6. Glomerular filtration rate (eGFR) \< 45 mL/min/1.73m² (MDRD formula).
7. Having a history of hospitalization due to hypertensive crisis within one year before randomization for enrollment.
8. Suffering from type 1 diabetes.
9. Suffering from primary pulmonary hypertension.
10. Being allergic to contrast agents.
11. Severe cardiac valve stenosis.
12. Cardiac insufficiency (NYHA class III - IV).
13. Hyperthyroidism or hypothyroidism.
14. Requiring mechanical ventilation for assisted breathing (except for nocturnal respiratory support for treating sleep apnea).
15. Acute or severe systemic infection.
16. Having an implantable cardioverter - defibrillator (ICD) or pacemaker.
17. Having obvious symptoms of active peptic ulcer (such as abdominal pain, nausea, vomiting, regurgitation, etc.).
18. Having obvious bleeding tendency and hematological diseases.
19. Having a history of surgery or trauma requiring hospitalization within 30 days before randomization for enrollment.
20. Having a cardiovascular event (stable or unstable angina, myocardial infarction) or cerebrovascular event (stroke, cerebrovascular accident, transient ischemic attack) within 6 months before randomization for enrollment.
21. Pregnant, lactating women, or women planning to become pregnant during the study period.
22. Currently participating in other clinical trials of drugs or medical devices.
23. Other reasons that the investigator deems inappropriate for participation in this study

Tratamiento, grupos y participación

El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.

Asignación

Asignación al azar

Enmascaramiento

Enmascaramiento cuádruple

Qué evalúan los investigadores

Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.

Medidas principales

Medidas secundarias

Centros de investigación (1)

El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.

1 centros

Equipo y fechas

Patrocinador principal

Shenzhen Pulsecare Medical Technology Co., Ltd.

Inicio del estudio

25 ene 2025 Real

Finalización primaria

2027-12 Estimado

Finalización del estudio

2030-12 Estimado

Primera publicación

14 mar 2025 Real

Última actualización

10 nov 2026 Real

Contactos oficiales del estudio

No hay un contacto central indicado. Revisa los centros y el registro oficial.